---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-038593"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2022-10-27T23:59:59+00:00"
generated_at: "2026-06-22T23:32:06.187738+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Insmed Q3 revenue $67.7M (+45% YoY); net loss $1.09/share; secures $775M financing

## Summary
- ARIKAYCE total revenue of $67.7M: $49.5M U.S., $14.5M Japan, $3.7M Europe/RoW.
- Net loss of $131.1M ($1.09 per share) vs $112.7M ($0.96) in Q3 2021.
- Cash and marketable securities $513.3M; strategic financings added $775M gross proceeds.
- Full-year 2022 ARIKAYCE revenue expected to grow at least 30% YoY.
- Phase 3 ASPEN (brensocatib) enrollment on track; topline data expected Q2 2024.

## SEC filing metadata
- accession: 0001140361-22-038593
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2022-10-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036122038593/0001140361-22-038593-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036122038593/brhc10043308_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-038593
- JSON: https://secwatch.observer/filing/0001140361-22-038593.json
- Plain text: https://secwatch.observer/filing/0001140361-22-038593.txt

## Key facts
- Earnings Releases
  INSMED Inc reported full-year 2022 results: revenue at least 30% year over year. Guidance reaffirmed.
  - Period: full-year 2022
  - Revenue: at least 30% year over year
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Insmed continues to expect full-year 2022 global revenues for ARIKAYCE to increase at least 30% year over year from 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1104506/000114036122038593/0001140361-22-038593-index.htm
- Earnings Releases
  INSMED Inc reported three months ended September 30, 2022 results: net income $131.1 million, EPS $1.09.
  - Period: three months ended September 30, 2022
  - Net income: $131.1 million
  - EPS: $1.09
  - Result: reported results
  source text: Insmed reported a net loss of $131.1 million, or $1.09 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1104506/000114036122038593/0001140361-22-038593-index.htm
- Earnings Releases
  INSMED Inc reported three months and nine months ended September 30, 2022 results: revenue $67.7 million, net income $131.1 million, EPS $1.09. Guidance reaffirmed.
  - Period: three months and nine months ended September 30, 2022
  - Revenue: $67.7 million
  - Net income: $131.1 million
  - EPS: $1.09
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total revenue for the third quarter ended September 30, 2022, was $67.7 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1104506/000114036122038593/0001140361-22-038593-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.